IFI16 and cervical carcinoma: By promoting tumor progression and contributing to an immunosuppressive microenvironment, IFI16 presents a potential therapeutic target to restore immune surveillance and improve treatment outcomes in HPV-positive cervical cancer (Figure 4) (53).